Genfit (Genfit) Total Current Assets : $123.35 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Genfit Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Genfit's total current assets for the quarter that ended in Dec. 2023 was $123.35 Mil.

Genfit Total Current Assets Historical Data

The historical data trend for Genfit's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Total Current Assets Chart

Genfit Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

323.06

224.72

302.93

167.86

123.35

Genfit Quarterly Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															-	167.86	145.82	-	123.35

Genfit Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Genfit's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	84.829	+	35.667	+	0.004	+	2.853
	=	123.35

Genfit's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	84.829	+	35.667	+	0.004	+	2.853
	=	123.35

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Genfit (OTCPK:GNFTF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Genfit's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	84.829	-	115.508	+	0.75 * 20.203	+	0.5 * 0.004
=	-15.52

Genfit Total Current Assets Related Terms

Thank you for viewing the detailed overview of Genfit's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Genfit (Genfit) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (OTCPK:GNFTF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

GNFT:USA 0QT6:UK GNFT:France XUPB:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.